These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25187697)

  • 1. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.
    Ohyashiki JH; Ohtsuki K; Mizoguchi I; Yoshimoto T; Katagiri S; Umezu T; Ohyashiki K
    Drug Des Devel Ther; 2014; 8():1151-9. PubMed ID: 25187697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
    Ohyashiki K; Umezu T; Katagiri S; Kobayashi C; Azuma K; Tauchi T; Okabe S; Fukuoka Y; Ohyashiki JH
    Int J Mol Sci; 2016 Apr; 17(4):570. PubMed ID: 27092489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.
    Mizoguchi I; Yoshimoto T; Katagiri S; Mizuguchi J; Tauchi T; Kimura Y; Inokuchi K; Ohyashiki JH; Ohyashiki K
    Cancer Sci; 2013 Sep; 104(9):1146-53. PubMed ID: 23758044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
    Flamant S; Ritchie W; Guilhot J; Holst J; Bonnet ML; Chomel JC; Guilhot F; Turhan AG; Rasko JE
    Haematologica; 2010 Aug; 95(8):1325-33. PubMed ID: 20460641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
    San José-Enériz E; Román-Gómez J; Jiménez-Velasco A; Garate L; Martin V; Cordeu L; Vilas-Zornoza A; Rodríguez-Otero P; Calasanz MJ; Prósper F; Agirre X
    Mol Cancer; 2009 Sep; 8():69. PubMed ID: 19723306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
    Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.
    Giallongo C; La Cava P; Tibullo D; Barbagallo I; Parrinello N; Cupri A; Stagno F; Consoli C; Chiarenza A; Palumbo GA; Di Raimondo F
    BMC Cancer; 2013 Feb; 13():60. PubMed ID: 23383963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
    de Lima LT; Vivona D; Bueno CT; Hirata RD; Hirata MH; Luchessi AD; de Castro FA; de Lourdes F Chauffaille M; Zanichelli MA; Chiattone CS; Hungria VT; Guerra-Shinohara EM
    Med Oncol; 2014 Mar; 31(3):851. PubMed ID: 24469953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
    Ferreira AF; de Oliveira GLV; Tognon R; Collassanti MDS; Zanichelli MA; Hamerschlak N; de Souza AM; Covas DT; Kashima S; de Castro FA
    Acta Haematol; 2015; 133(4):354-364. PubMed ID: 25721555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
    Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
    PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
    Smith BD; Kasamon YL; Kowalski J; Gocke C; Murphy K; Miller CB; Garrett-Mayer E; Tsai HL; Qin L; Chia C; Biedrzycki B; Harding TC; Tu GH; Jones R; Hege K; Levitsky HI
    Clin Cancer Res; 2010 Jan; 16(1):338-47. PubMed ID: 20048335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
    Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
    J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
    Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
    Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.